CULVER CITY, Calif.--(EON: Enhanced Online News)--NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company and TransMed Systems, a company that develops and deploys software solutions that facilitate exploration, reporting, and analysis of clinical, molecular, and healthcare operational data, announced today that they have entered into a partnership to give cancer centers across the country the ability to easily share data that can help improve outcomes and expedite cancer research. The partnership is an important operational milestone of the QUILT Programs (Quantum Immuno-oncology Lifelong Trial) designed to harness and orchestrate all the elements of the immune system through testing of novel treatment combinations.
“We’re excited about the potential of this partnership and look forward to revolutionizing clinical trial identification and recruitment for the cancer community.”
The two California-based companies will deploy the offerings throughout the Quality Cancer Care Alliance (QCCA) and the National Cancer Care Alliance (NCCA) sites over the next year. Throughout the network, participating community oncologists are leveraging GPS Cancer™ molecular profiling—a unique, comprehensive set of tests integrating quantitative proteomics, and whole genome (DNA) and transcriptome (RNA) sequencing.
TransMed’s Clinical Practice Suite will provide oncology practices with applications that identify treatment options and historical outcomes for a group of similar patients, including a precision medicine report. Each patient population report will include patient count, mean survival time, death rate, and any complication associated with a particular treatment. This is made possible through TransMed’s Precision Medicine Platform, a patented data science which has been supporting other major consortiums around the world.
“We are thrilled to join forces with TransMed to provide community oncologists with access to data to support their efforts and understand the underlying mechanisms of cancer,” stated Patrick Soon-Shiong, M.D., founder and CEO of NantHealth. “Oncologists throughout the country are constantly searching for trials that fit their specific patients’ needs. This initiative creates the opportunity for patients to access new and existing trials under the QUILT program.”
“At TransMed Systems, we are constantly working to develop and deliver software tools that facilitate the analysis and application of translational data,” stated Nick Berens, Chairman and CEO at TransMed. “We’re excited about the potential of this partnership and look forward to revolutionizing clinical trial identification and recruitment for the cancer community.”
“Through this partnership, we are ensuring that patients at community oncology centers have access to quality clinical trials right in their own backyard,” stated Carla Balch, President of NantCare and SVP of Clinical Strategy at NantKwest. “In partnership with TransMed, we are opening the doors of possibility for these patients and their oncologists to ultimately accelerate research for cancer patients.”
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients, as well as our contribution to the Cancer 2020 initiative. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.
NantCare, a member of the NantWorks ecosystem of companies, is committed to ensuring every cancer patient has access to true immunotherapy clinical trials (QUILT) or optimized treatment based on GPS Cancer Scan results. By organizing all relevant data and making it available for the world, NantCare aims to spread oncology-related intelligence to maximize support of patients, physicians and life science companies. NantCare embraces life science company partnerships and strives to developing treatments guided by genomic, transcriptomic and quantitative proteomic data. By supporting community oncology clinically and financially, NantCare is ensuring they continue to serve the majority of cancer patients in the US.
About GPS Cancer™
GPS Cancer™ is a comprehensive molecular profile available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with unprecedented insight into the molecular signature of each patient’s cancer to inform personalized treatment strategies. GPS Cancer profiling is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for the QUILT programs. For more information, visit www.gpscancer.com.
NantHealth, Inc. a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About TransMed Systems
TransMed Systems develops and deploys software solutions that facilitate exploration, reporting, and analysis of clinical, molecular, and healthcare operational data. TransMed’s BIS provides an integrated bio-informatics platform enabling clinical and research organizations to aggregate data from multiple sources, easily explore data, and perform research and/or practice specific analysis. TransMed’s platform unlocks the potential of the healthcare repository by tightly integrating analytics with aggregated data providing selfservice analysis of all bio-clinical data sources in a framework usable by clinicians and investigators. Our solutions are used by health sciences researchers as well as clinicians interested in the application of information technology to the challenges of basic research and turning research into improved clinical practices. Our Bioinformatics solution is composed of four core capabilities leveraging our meta-data driven repository that aggregates data from disparate health data sources.